PolyPeptide Group AG (FRA:8H0)

Market Cap	1.38B +105.7%
Revenue (ttm)	389.33M +15.6%
Net Income	-21.17M
EPS	-0.64
Shares Out	n/a
PE Ratio	n/a
Forward PE	83.74
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	5
Open	41.60
Previous Close	41.40
Day's Range	41.60 - 41.60
52-Week Range	20.75 - 44.20
Beta	n/a
RSI	60.03
Earnings Date	Aug 13, 2026

About PolyPeptide Group AG

PolyPeptide Group AG operates as a contract development and manufacturing company in Europe, the United States, Asia Pacific, and internationally. It develops and manufactures synthetic peptides used as active pharmaceutical ingredients or intermediates in therapeutic products. The company offers portfolio of drug therapies for metabolic diseases, including the GLP-1. It also provides generic peptides and peptides used in cosmetics, animal health, and medical devices, as well as development and analytical services. The company serves academic, ...

• Industry: Commercial Physical and Biological Research
• Founded: 1952
• Employees: 1,440
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 8H0

Financial Performance

In 2025, PolyPeptide Group AG's revenue was 389.33 million, an increase of 15.60% compared to the previous year's 336.79 million. Losses were -21.17 million, 8.20% more than in 2024.